Therapeutics Discovery from Bench to First In-Human Trials

October 10, 2017 – October 12, 2017

Abstract submission starts 1 May 2017

Therapeutics Discovery, Phase 1 and early phase clinical trial activities are the target of Kingdom of Saudi Arabia to enter the world of making and marketing new medicines.

In the last decade 56% of novel therapies are originated from the Academia and Biotech companies and 71% were “me-too” drugs coming from the Pharmaceutical companies.

The challenge for introducing new therapies into the market or development pipeline is based on the better understanding of the diseases biology and it is becoming apparent that the “single target for single disease” may be an outdated concept. A new approach being pursued is to dissect the molecular basis of the diseases and in this regard, a future trend includes using the immune system and cell therapy to fight the diseases to discover and develop new therapies for inflammatory and proliferative diseases. Also there is a focus to develop better drug delivering system based on Nanotechnology.

Based on this concept, KAIMRC as a prime biomedical research institute in the KSA and the region, is leading the path to establish therapeutics discoveries and development platforms. Moreover, with renowned researchers, medical doctors, experts and professional clinical trial facilities, KAIMRC is playing important roles in clinical trials aiming to enter phase 1 and early phase new drug development.

KAIMRC conference on “Therapies Discoveries From Bench to First In Humans Trials” will provide an interdisciplinary forum for scientific investigators interested in the latest trend in therapeutics discoveries approaches, advanced drug delivery system and clinical trials that would be covered in the following sessions: 


  • Phase I Clinical Trials: Challenges and Opportunities
  • Disease Specific Early Clinical Trials
  • Therapeutics Discovery: Niches and Paradigm
  • Advanced and Targeted Drug Delivery Technologies
  • Small molecule drugs vs Biologicals (Antibody and CART)

KAIMRC conference will provide a new platform where experts from Kingdom of Saudi Arabia, Arab World, North America, Europe and Asia will share their insight and wisdom on the latest trends on new therapeutic discoveries and development in various disease areas, in Kingdom of Saudi Arabia and worldwide. The conference aims to provide a highly focused think-tank atmosphere for a select group of participants. About 10 speakers, chosen from among the top international researchers in their field of Phase 1 clinical Trials and therapeutic discoveries, will be joined by a limited number of participants, selected on the basis of their scientific experience, for an intensive three-day hands-on discussion of the latest research in their field.


  1. Abstracts submitted will be selected for oral presentations and poster.
  2. Abstracts should not exceed 250 words.
  3. Abstracts should include the following sections: Title, Authors, Affiliation, Background, Objective(s), method(s), result(s) and conclusion.

Instructions for submitting a new abstract as an Author:
1. Click the ‘LOG IN’ tab at the top of the page.

2. If you have previously registered for an old event, just provide your username /password and click ‘login’
I. Click the ‘Author’ link to submit the abstract.


III. Step one: You must make sure that all items in the submission checklist are checked and satisfied before continuing and clicking ’save and continue’.

IV. Step two: fill in all the required fields then click ‘save and continue’.

V. Your abstract has been successfully submitted.

3. If this is your first time registering Click on ‘Not a user? Create an account with this site’.
I. Fill in all the required fields and make sure to select the Author role in “Create Account as” section then click on ‘Create’ . After that follow the previous steps to submit an abstract.

Click here for farther clarifications

Conference Information